Investor Presentaiton

India (Rx + Gx) Sales Rs Cr Q1 Y-o-Y Q1 Q-o-Q Rs Cr 1800 1800 +22% 1544 1600 14% 1544 1600 1353 1400 1400 1270 1200 1200 1000 1000 800 800 600 600 400 400 200 0 200 0 Q1 FY 18 Q1 FY 19 Q4 FY18 Q1 FY19 Cipla Key Business Highlights¹ Key therapeutic areas delivered above market performance which includes Cardiac (11.3% Vs Mkt 7.5%), Respiratory (11.2% Vs Mkt 9.1%), Urology (14.5% Vs Mkt 13.1%) and CNS (7% Vs Mkt 4.7%) Continued leadership position in Respiratory and Urology and ranked amongst top 5 in CNS, Cardiac and Anti-infectives Strategic partnership with Roche India: Strengthened Oncology portfolio with the launch of 3 MABS (Bevacizumab, Trastuzumab & Rituximab) Diabetes franchise development: Partnered with Eli Lilly to market and distribute insulin glargine injection (Basaglar)² 1. IQVIA (IMS) MAT Jun' 18 | 2. Upon final approval Investor Presentation: Q1FY19 08-08-2018 6

View entire presentation